A Phase 1/2 interventional study of ALE.P03 and ALE.P03 in Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer and Colorectal Cancer, sponsored by Alentis Therapeutics AG. Recruiting at 41 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Alentis Therapeutics AG · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Colorectal Neoplasms with a site in Spain — 97 open to participants now, 150 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.
Among the 463 studies in Colorectal Neoplasms with a site in Spain, this one is the 195th largest by planned enrollment of the 405 interventional ones that give a count, is one of 34 that started in 2025, is one of 67 in phase 1/2, reaches primary completion later than 122 of the 149 other live ones, and was the 437th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →97 of the 463 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Verastem, Inc. · Sites in Spain, United States, Australia and 2 more countries
Ages 18+
Blueprint Medicines Corporation · Sites in Spain, United States
Ages 18+
Maimónides Biomedical Research Institute of Córdoba · Sites in Spain
Ages 18–75
AbbVie · Sites in Spain, United States, Belgium and 8 more countries
Ages 18+
Gilead Sciences · Sites in Spain, United States, Australia and 1 more country
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 146 · Phase 2 192 · Phase 3 73 · Phase 4 7
First in 1993; this study’s year is marked. 34 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 167 across the 405 interventional studies, 400 across the 55 observational. Of the 282 that completed or were terminated, 125 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
300 of 463 have an industry lead sponsor. The 10 most frequent:
Alentis Therapeutics AG is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Alentis Therapeutics AG has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
41 of the studies in Colorectal Neoplasms with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT05988645MiWEndo Solutions S.L.Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II) | 2026-11-29 |
| NCT05789069HiFiBiO TherapeuticsA Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
Add all 41 to your calendar (.ics) → With an account.
Among the 463 studies in Colorectal Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with selected squamous solid tumors.
This Study has a Phase I ALE.P03 monotherapy dose escalation and recommended dose for expansion (RDE) study and a Phase II study of ALE.P03 as monotherapy at RP2D in adult patients with selected advanced or metastatic Claudin-1 positive (CLDN1+) cancers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase I Dose Escalation:
- Received and being /intolerant to available systemic standard of care (SOC) regimens (based on local institutional guidelines) for advanced disease.
Phase I RDE and Phase II:
Applicable for Phase I Dose Escalation, Phase I RDE and Phase II:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive ALE.P03 as monotherapy via intravenous infusion. The ALE.P03 will be given at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended dose for expansion (RDE) is determined in Phase I dose escalation part of the study.
Drug: ALE.P03
Patients will receive ALE.P03 as monotherapy via intravenous infusion. The safe recommended doses of ALE.P03 will be given in Phase I dose expansion part of the study to identify recommended Phase II dose (RP2D) for Phase II.
Drug: ALE.P03
Patients will receive ALE.P03 as monotherapy via intravenous infusion at the RP2D, or according to the dosing schedule after the dose expansion phase.
Drug: ALE.P03
ALE.P03, will be administered by IV infusion according to the assigned arms.
ALE.P03, will be administered by IV infusion according to the assigned arms.
ALE.P03, will be administered by IV infusion according to the assigned arms.
Number of Patients with Dose Limiting Toxicities (DLTs) (Phase I)
DLTs as defined in the protocol will be assessed to evaluate safety and tolerability of ALE.P03 (Phase I Dose Escalation), and to establish RP2D for ALE.P03 (Phase I RDE).
Time frame: Up to 28 days
Number of Patients with Adverse Events (Phase I)
Adverse events will be assessed to evaluate safety and tolerability of ALE.P03 (Phase I Dose Escalation), and to establish RP2D for ALE.P03 (Phase I RDE).
Time frame: From Day 1 up to Safety follow-up (30 ± 5 days post last dose [Up to 4 years])
Overall Response Rate (ORR) (Phase I)
The ORR is the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) This is assessed to establish RP2D for ALE.P03 (Phase I RDE)
Time frame: From ALE.P03 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 4 years)
Duration of Response (DoR) (Phase I)
The DoR is defined for patients achieving a CR or PR as per Investigator review according to RECIST 1.1 to disease progression before new anti-cancer therapy or death of any cause, whichever occurs earlier. This is assessed to establish RP2D for ALE.P03 (Phase I RDE).
Time frame: From ALE.P03 treatment initiation until disease progression or study completion (Up to 4 years)
Overall Response Rate (ORR) (Phase II)
The ORR is assessed to assess anti-tumor activity of ALE.P03 (Phase II).
Time frame: From ALE.P03 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 4 years)
Duration of Response (DoR) (Phase II)
The DoR is defined for patients achieving a confirmed CR or PR as the time from the initial response of CR or PR to disease progression before new anti-cancer therapy or death of any cause, whichever occurs earlier. This is assessed to assess anti-tumor activity of ALE.P03 (Phase II).
Time frame: From ALE.P03 treatment initiation until disease progression or study completion (Up to 4 years)
Number of Patients with Adverse Events (Phase I RDE and Phase II)
Adverse events will be assessed to evaluate safety and tolerability of ALE.P03 (Phase I RDE and Phase II)
Time frame: From Day 1 up to Safety follow-up (30 ± 5 days post last dose [Up to 4 years]
Disease control rate (DCR) (Phase I and II)
The DCR is defined as the proportion of patients with a BOR of CR or PR or stable disease (SD) per Investigator review according to RECIST 1.1 at or prior to initiation of the use of new anti-cancer therapy. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P03 (Phase I and II).
Time frame: From ALE.P03 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 4 years)
Median Progression-Free Survival (PFS) rate at 6 and 12 Months (Phase I and II)
The PFS is defined as time from first study treatment to a documented disease progression according to RECIST 1.1, as determined by the Investigator, or death due to any cause, whichever occurs earlier. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P03 (Phase I and II).
Time frame: At 6 and 12 months after initiation of ALE.P03 treatment
Median Overall Survival (OS) rate at 6, 12, and 24 Months (Phase I and II)
The OS is defined as time from first study treatment to death due to any cause. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P03 (Phase I and II).
Time frame: At 6, 12, and 24 months after initiation of ALE.P03 treatment
Blood Concentration of ALE.P03 Antibody-drug Conjugate (ADC) (Phase I and II)
Concentrations of ALE.P03 ADC in blood will be measured at each scheduled time point per arms.
Time frame: Phase I and II: From Day 1 until at end of treatment visit (EoT) (Up to 4 years)
Blood Concentrations of Total Antibody (Phase I and II)
Concentrations of total antibody in blood will be measured at each scheduled time point per arms.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Blood Concentrations of Payload (Phase I and II)
Concentrations of payload in blood will be measured at each scheduled time point per arms.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Area under the concentration-time curve over the dosing interval (AUCtau) (Phase I and II)
The AUCtau of ALE.P03 will be measured to assess the pharmacokinetic (PK) profile of ALE.P03.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUClast) (Phase I and II)
The AUClast of ALE.P03 will be measured to assess the PK profile of ALE.P03.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time (AUCinf) (Phase I and II)
The AUCinf of ALE.P03 will be measured to assess the PK profile of ALE.P03.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Maximum Concentration (Cmax) (Phase I and II)
The Cmax of ALE.P03 will be measured to assess the PK profile of ALE.P03. It is determined directly from the concentration-time profile.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Minimum concentration (Cmin) (Phase I and II)
The Cmin of ALE.P03 will be measured to assess the PK profile of ALE.P03. It is determined directly from the concentration-time profile.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Concentration at the end of a dosing interval (Ctrough) (Phase I and II)
The Ctrough of ALE.P03 will be measured to assess the PK profile of ALE.P03.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
The terminal elimination rate constant (KeL) (Phase I and II)
The KeL of ALE.P03 will be measured to assess the PK profile of ALE.P03. It is determined by selection of at least three data points on the terminal phase of the concentration-time curve.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Terminal elimination half-life (t½) (Phase I and II)
The t½ of ALE.P03 will be measured to assess the PK profile of ALE.P03.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Time of Maximum Concentration (tmax) (Phase I and II)
The tmax of ALE.P03 will be measured to assess the PK profile of ALE.P03. It is determined directly from the concentration-time profile.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Average Concentration (Cavg) (Phase I and II)
The Cavg of ALE.P03 will be measured to assess the PK profile of ALE.P03.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Number of Patients with Presence of anti-ALE.P03 Antibodies (Phase I and II)
Presence of anti-ALE.P03 Antibodies will be assessed to evaluate the immunogenicity of ALE.P03.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Number of Patients with Positive anti-ALE.P03 Antibodies (Phase I and II)
Presence of anti-ALE.P03 Antibodies (positive/negative) will be assessed to evaluate the immunogenicity of ALE.P03.
Time frame: Phase I and II: From Day 1 until at EoT (Up to 4 years)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Apr 2029, 43 months after the start.
Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 43 months is below that.
Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alentis Therapeutics AG